RxDoctor Payments Data

Sereen Askar, NP

Family · Gretna, LANPI 1104377555

Payments from drug & device makers

$1,419in general payments, 2019–2025

Across 68 payments — averaging $20.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kyowa Kirin, Inc.$241
  • MDD US Operations, LLC$225
  • AbbVie$164
  • UCB, Inc.$112
  • Neurocrine Biosciences, Inc.$102
  • Eisai Inc.$86
  • plus $490 from 12 others

What the payments were for

  • Food & beverage$1,37497%
  • Education$453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,419 in reported general payments places this provider in the 65th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$25,787
Medicare patients
152
Services billed
311

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine17$116,416
IngrezzaValbenazine Tosylate12$102,515
RytaryCarbidopa/Levodopa62$99,276
GocovriAmantadine Hcl25$75,250
Droxidopa24$55,192
Rivastigmine55$11,235
Rasagiline Mesylate52$6,682
Carbidopa-LevodopaCarbidopa/Levodopa206$6,161
Selegiline Hcl16$2,816
AmantadineAmantadine Hcl40$2,160
Donepezil Hcl163$1,634
Entacapone12$1,602
Ropinirole ErRopinirole Hcl13$1,274
Carbidopa-Levodopa ErCarbidopa/Levodopa38$1,063
RivastigmineRivastigmine Tartrate28$1,028

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$78$116,41617 claims
Neurocrine Biosciences, Inc.Ingrezza$102$102,51512 claims
MDD US Operations, LLCGocovri$225$75,25025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,610 family providers in Louisiana.

Other family in Gretna

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →